Back to Search Start Over

High DEPTOR expression correlates with poor prognosis in patients with esophageal squamous cell carcinoma.

Authors :
Nan-bo Liu
Jun-hua Zhang
Yu-fan Liu
Jun Li
Zhen-zhong Zhang
Ji-wei Li
Wen-yue Liu
Chen Huang
Tao Shen
Cheng-wei Gu
Dong-yun Gao
Xia Wu
Xu Wu
Source :
OncoTargets & Therapy. Nov2015, Vol. 8, p3449-3455. 7p.
Publication Year :
2015

Abstract

Objective: The disheveled, Egl-10, and pleckstrin (DEP) domain containing mammalian target of rapamycin (mTOR)-interacting protein (DEPTOR) is a binding protein containing mTOR complex 1 (mTORC1), mTOR complex 2 (mTORC2), and an endogenous mTOR inhibitor. DEPTOR shows abnormal expressions in numerous types of solid tumors. However, how DEPTOR is expressed in esophageal squamous cell carcinoma (ESCC) remains elusive. Methods: The expression of DEPTOR in 220 cases of ESCC and non-cancerous adjacent tissues was detected by immunohistochemistry. DEPTOR levels in ESCC and paired normal tissue were quantified using reverse transcription-polymerase chain reaction and Western blot analysis to verify the immunohistochemical results. The relationship between DEPTOR expression and the clinicopathological features of ESCC was analyzed based on the results of immunohistochemistry. Finally, we analyzed the relationship between DEPTOR expression and the prognosis of patients with ESCC. Results: Immunohistochemical staining showed that the expression rate of DEPTOR in ESCC tissues was significantly increased. DEPTOR mRNA and protein expression was significantly higher in ESCC tissues than in normal adjacent esophageal squamous tissues. High DEPTOR expression was significantly correlated with regional lymph node status in the TNM stage of patients with ESCC. Kaplan-Meier survival curves showed that the rate of overall survival was significantly lower in patients with high DEPTOR expression than in those with low DEPTOR expression. Additionally, high DEPTOR expression was an independent prognostic predictor for ESCC patients. Conclusion: High DEPTOR expression is an independent prognostic biomarker indicating a worse prognosis for patients with ESCC. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
11786930
Volume :
8
Database :
Academic Search Index
Journal :
OncoTargets & Therapy
Publication Type :
Academic Journal
Accession number :
111385092
Full Text :
https://doi.org/10.2147/OTT.S92862